monoclonal antibodies against SARS-CoV-2

Monoclonal antibodies against SARS-CoV-2 are a class of recombinant neutralizing antibodies designed to target the spike (S) glycoprotein of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). By binding specifically to epitopes on the receptor-binding domain (RBD) or the N-terminal domain (NTD) of the spike protein, these antibodies block the interaction between the virus and the host cell receptor angiotensin-converting enzyme 2 (ACE2), thereby preventing viral entry and replication. Developed rapidly during the COVID-19 pandemic, several of these agents (such as bamlanivimab, etesevimab, casirivimab, imdevimab, sotrovimab, and tixagevimab/cilgavimab) received emergency use authorizations or approvals for the treatment and pre-exposure prophylaxis of mild-to-moderate COVID-19 in high-risk patients. However, their clinical utility has been significantly challenged by the emergence of SARS-CoV-2 escape variants, particularly Omicron sublineages, which harbor mutations that evade neutralization by many first-generation monoclonal antibodies.

Other names

anti-SARS-CoV-2 mAbsanti-SARS-CoV2 mAbsanti-SARS-CoV 2 mAbsneutralizing monoclonal antibodies against SARS-CoV-2SARS-CoV-2 monoclonal antibodiesSARS-CoV2 monoclonal antibodiesSARS-CoV 2 monoclonal antibodies